IGC Pharma Inc IGC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IGC is a good fit for your portfolio.
News
-
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
-
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
-
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
-
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
-
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
-
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
-
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
-
IGC Pharma to Attend BIO International Convention 2024
Trading Information
- Previous Close Price
- $0.45
- Day Range
- $0.44–0.46
- 52-Week Range
- $0.25–0.91
- Bid/Ask
- $0.44 / $0.45
- Market Cap
- $33.96 Mil
- Volume/Avg
- 90,748 / 328,275
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 67
- Website
- https://www.igcinc.us
Valuation
Metric
|
IGC
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.09 |
Price/Sales | 19.64 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
IGC
|
---|---|
Quick Ratio | 0.55 |
Current Ratio | 1.58 |
Interest Coverage | — |
Quick Ratio
IGC
Profitability
Metric
|
IGC
|
---|---|
Return on Assets (Normalized) | −31.75% |
Return on Equity (Normalized) | −38.22% |
Return on Invested Capital (Normalized) | −36.92% |
Return on Assets
IGC
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Yqyshbfqd | Lxg | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Hqkhpwdr | Dzykzv | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Fgdjbywm | Zxsxnl | $118.7 Bil | |||
Moderna Inc
MRNA
| Lwtzrkc | Jncy | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Dsrlhzth | Rzxny | $29.7 Bil | |||
argenx SE ADR
ARGX
| Hcjxkrbs | Qfpb | $28.8 Bil | |||
BioNTech SE ADR
BNTX
| Ytrzjhcq | Vbzk | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Yznjhmzb | Kqmwy | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Vttqwmxc | Kkwpv | $15.0 Bil | |||
Incyte Corp
INCY
| Nsjdxrgms | Zvdyrp | $13.5 Bil |